Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Placebo 40 mg

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,920 result(s) found for: Placebo 40 mg. Displaying page 1 of 196.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-001021-28 Sponsor Protocol Number: 1208.22 Start Date*: 2005-09-05
    Sponsor Name:Boehringer Ingelheim GmbH
    Full Title: .A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to assess the efficacy and safety of duloxetine (20 mg bid for 2 weeks escalating to 40 mg bid) for up to 1...
    Medical condition: stress urinary incontinence and stress predominant mixed urinary incontinence
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) SE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004545-32 Sponsor Protocol Number: EP-002 Start Date*: 2020-04-16
    Sponsor Name:Empros Pharma AB
    Full Title: Lean Efficacy Phase IIa Proof of concept trial (LEAAP). A multi-centre, double-blind, placebo controlled, randomised study in overweight and obese patients during twenty-six weeks, investigating th...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-011006-42 Sponsor Protocol Number: vs.3.23-02-2009 Start Date*: 2009-07-13
    Sponsor Name:Rigshospitalet, Hjertemedicinsk afd. B
    Full Title: Sildenafil and diastolic dysfunction after AMI
    Medical condition: Diastolic dysfunction
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052337 Diastolic dysfunction LLT
    9.1 10052337 Diastolic dysfunction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004543-57 Sponsor Protocol Number: D9618C00001 Start Date*: 2006-03-29
    Sponsor Name:AstraZeneca AB
    Full Title: A 6-month randomized, double-blind, parallel-group, multicentre, placebo-controlled Phase II study to compare anti-asthmatic effect and safety of esomeprazole (Nexium) 40 mg twice daily or 40 mg on...
    Medical condition: Moderate to severe asthma and symptoms of gastroesophageal reflux disease (GERD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) IT (Completed) SK (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004575-74 Sponsor Protocol Number: CAIN457FDE03 Start Date*: 2016-03-16
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blind, placebo-controlled multicenter study of Secukinumab (AIN457) to examine the clinical efficacy and the NSAID-sparing effect of Secukinumab over 16 weeks in patients with ...
    Medical condition: Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010116-15 Sponsor Protocol Number: CTU 052 D Start Date*: 2010-05-31
    Sponsor Name:RIEMSER Arzneimittel AG
    Full Title: A multicentre double blind placebo controlled clinical dose- finding study for three doses of Antiadipositum X 112 T® (Cathine-hydrochloride) vs. placebo in 240 patients with a body mass index (BMI...
    Medical condition: diet-related obesity diagnosed by BMI of 30 to 40 kg/m² or diet-related obesity diagnosed by BMI of 27 to 40 kg/m² in patient with coexisting risk factors like hyperlipidaemia, type 2 diabetes mell...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003197-41 Sponsor Protocol Number: DFD-29-CD-002 Start Date*: 2017-01-19
    Sponsor Name:Dr. Reddy's Labaratories Ltd.
    Full Title: A Multi-Center, Randomized, Double-Blind, Parallel-Group, Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory...
    Medical condition: Inflammatory Lesions of papulopustular Rosacea
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10076537 Papulopustular rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000314-12 Sponsor Protocol Number: SC2-90049-003 Start Date*: 2005-10-14
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Effect of 3 doses (20, 40 and 60 mg) of a sublingual formulation of piribedil (S 90049) in combination with levodopa on end-of-dose fluctuations in advanced Parkinson’s disease patients after a 14-...
    Medical condition: Parkinson's Disease aggravated
    Disease: Version SOC Term Classification Code Term Level
    7.0 10034006 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003509-18 Sponsor Protocol Number: NAC0606 Start Date*: 2007-08-13
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian Health Board
    Full Title: Mechanisms for the effect of acetylcysteine on renal function after exposure to radiographic contrast material
    Medical condition: Radiocontrast-induced nephropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002844-24 Sponsor Protocol Number: H6D-MC-LVGX Start Date*: 2006-04-10
    Sponsor Name:Lilly ICOS LLC
    Full Title: A Double-Blind, Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hyperte...
    Medical condition: Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterised by elevation of pulmonary artery pressure and pulmonary vascular resistance, leading to right heart failure ...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002441-39 Sponsor Protocol Number: D961DC00001 Start Date*: 2005-11-07
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised, double-blind, parallel-group, placebo controlled study of esomeprazole i.v. (bolus infusion of 80 mg followed by a continuous infusion of 8 mg per hour) administered for 72 hours to a...
    Medical condition: Gatrointestinal haemorrhages NEC. (Bleeding gastric or duodenal ulcer will be investigated). MedDRA classification code Level: HLGT = High Level Group Term. See below.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10017959 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) SE (Completed) NO (Completed) DK (Completed) ES (Completed) AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003723-29 Sponsor Protocol Number: JBT101-CF-002 Start Date*: 2018-05-11
    Sponsor Name:Corbus Pharmaceuticals, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
    Medical condition: Cystic Fibrosis (CF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) SE (Completed) FR (Completed) PT (Completed) SK (Completed) AT (Completed) BE (Completed) ES (Completed) BG (Completed) NL (Completed) CZ (Completed) GR (Completed) PL (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-000419-90 Sponsor Protocol Number: T-EE05-135 Start Date*: 2006-06-16
    Sponsor Name:TAP Pharmaceutical Products Inc.
    Full Title: A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis
    Medical condition: Erosive esophagitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) HU (Completed) SK (Completed) CZ (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2021-002006-27 Sponsor Protocol Number: CKJX839B12302 Start Date*: 2021-11-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease...
    Medical condition: Atherosclerotic cardiovascular disease (ASCVD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned) HU (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) SI (Trial now transitioned) BG (Trial now transitioned) HR (Trial now transitioned) NO (Trial now transitioned) PL (Trial now transitioned) FI (Trial now transitioned) GR (Trial now transitioned) IS (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003258-87 Sponsor Protocol Number: DRI6091 Start Date*: 2006-03-09
    Sponsor Name:Sanofi Aventis Deutschland GmbH
    Full Title: Efficacy and safety of intra-articular multiple doses of 500 µg icatibant including 40 mg triamcinolone as calibrator in a randomized, double-blind, parallel-group, placebo-controlled 13-week multi...
    Medical condition: Subjects with painful osteoarthritis in the knee
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) SI (Completed) LT (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2017-002143-15 Sponsor Protocol Number: RLM-MD-03 Start Date*: 2018-11-06
    Sponsor Name:Allergan Ltd.
    Full Title: A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) LV (Prematurely Ended) HU (Completed) FR (Completed) BE (Completed) DK (Prematurely Ended) BG (Completed) AT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001580-22 Sponsor Protocol Number: 062 Start Date*: 2004-12-21
    Sponsor Name:MSD SHARP & DOHME GMBH
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sito...
    Medical condition: Homozygous Sitosterolemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005839-76 Sponsor Protocol Number: PDE5I-UPR-AAR-01 Start Date*: 2021-02-15
    Sponsor Name:University hospital Bispebjerg and Frederiksberg, Department of Clinical Pharmacology
    Full Title: Effects of single dose tadalafil on urethral and anal closure function and on urinary flow in healthy females: A randomised, controlled, double-blinded, two-period cross-over study
    Medical condition: Urinary stress incontinence and fecal incontinence
    Disease: Version SOC Term Classification Code Term Level
    22.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003091-39 Sponsor Protocol Number: APHP180158 Start Date*: 2020-02-10
    Sponsor Name:Assistance Publique des Hôpitaux de Paris
    Full Title: To relieve dyspnea with low dose titration of morphine in patients admitted to intensive care for acute respiratory failure: A pilot study - OPIDYS
    Medical condition: Adult patients admitted to intensive care for ARI: severe dyspnea (defined by a visual analogue dyspnea scale (EVA-dyspnea) ≥ 40)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004907-39 Sponsor Protocol Number: D0170C00009 Start Date*: 2005-03-04
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, double-blind, randomized, cross-over, international, multicentre study to evaluate the analgesic efficacy of 3 weeks oral administration of AZD4282 300 mg b.i.d. compared with placebo i...
    Medical condition: Diagnostic of Post Traumatic Neuralgia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 03 18:04:31 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA